> ## Content Index > Fetch the complete content index at: https://compounded.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # Medicare Agreed to Pay for a Procedure That Lowers Blood Pressure by a Few Points. The Conditions Attached Are the Real Story - URL: https://compounded.ghost.io/medicare-agreed-to-pay-for-a-procedure-that-lowers-blood-pressure-by-a-few-points-the-conditions-attached-are-the-real-story/ - Published: 2026-10-05T10:17:11.000Z - Updated: 2026-10-05T10:17:10.000Z - Author: Connor Hayes CMS finalised coverage for renal denervation last October, three years after the first device was approved, and the 2025 ACC and AHA blood pressure guidelines list it as an adjunctive option for uncontrolled hypertension. The procedure threads a catheter into the arteries feeding the kidneys and uses radiofrequency energy or ultrasound to interrupt the sympathetic nerves running along them. In sham-controlled trials the blood pressure reductions are consistent and small: roughly 4 to 7 mm Hg at two to six months depending on the device and whether patients were on medication, with one cohort showing 10 mm Hg at three years. The conditions CMS attached to payment say more about where this fits than the numbers do. ### From the Lab to the Ledger The nerves in question run in the wall of the renal arteries and carry signals in both directions. Outgoing sympathetic traffic tells the kidney to retain sodium, constrict its vessels and release renin, which raises pressure through several routes at once. Incoming signals feed back to the brain and sustain sympathetic tone systemically. Interrupting that loop lowers pressure without a daily pill, which is the entire appeal. The field nearly died once. An early sham-controlled trial in 2014 failed, and the honest reading afterwards was that earlier positive results had been driven by the placebo effect of the procedure and by patients taking their medication more carefully while enrolled in a study. What rescued it was better trial design and better technique: sham controls throughout, ambulatory monitoring rather than office readings, and catheters that treat the smaller branch arteries where much of the nerve supply actually sits. What came back is a real but modest effect. A 4 to 7 mm Hg reduction is worth having at a population level, where a few points across many people prevents a meaningful number of strokes. For an individual, it is roughly what one additional medication would deliver, and the durability data out to three years is the part that distinguishes it, since it does not depend on remembering to take anything. CMS did not simply agree to pay. Coverage runs through coverage with evidence development, meaning treatment inside approved studies, and the patient conditions are strict: pressure above 140 over 90 despite management, at least six weeks on stable maximally tolerated guideline-directed therapy, screening for secondary causes including primary aldosteronism and sleep apnea, and at least six months of primary care coordination with three or more encounters before referral. Operators need ten supervised renovascular procedures and five proctored cases per device. Read plainly, that is a payer saying the procedure belongs at the end of a workup rather than in place of one, and building the workup into the payment rule. ### Bio-Pipeline Ledger Renal denervation with the approved radiofrequency and ultrasound systems: FDA approved, guideline-endorsed as adjunctive therapy, and covered by Medicare only within approved studies and the conditions above. Screening for secondary hypertension, particularly primary aldosteronism: established, underused, and now a prerequisite for coverage. A substantial share of resistant hypertension has an identifiable cause with its own specific treatment. Guideline-directed medication at maximally tolerated doses: the intervention with decades of outcome evidence behind it, and the comparison any procedure has to beat. Ambulatory or home blood pressure monitoring: the way apparent resistance is confirmed, and the step that reclassifies a share of patients before anyone considers a catheter. Cardiovascular outcome data for renal denervation, meaning strokes and heart attacks prevented: not yet demonstrated. The trials measured blood pressure. Adherence itself: the most common reason a regimen appears to fail, addressable without a procedure, and the thing the six-month coordination requirement is quietly designed to surface. ### The Clinical Reality Check What is established is that renal denervation lowers blood pressure by a small, reproducible amount in sham-controlled trials, that the reduction appears durable for at least three years, and that regulators and guideline committees now consider it a legitimate option at the end of the line. What is overstated is any framing of it as a cure or as a way off medication. The average effect is comparable to adding one drug, most patients remain on treatment afterwards, and no trial has yet shown that it prevents the events blood pressure control exists to prevent. The absence of outcome data is not a technicality in a field where a promising procedure already failed once under a sham control. For anyone whose pressure is genuinely not controlled, the practical sequence is the one CMS wrote into its rule, and it is worth walking through with a physician before anything else: confirm the readings outside the office, check for a secondary cause, review what is actually being taken and at what dose, and treat sleep apnea if it is there. If all of that is done and the numbers still will not move, this is now a real option, available through a hypertension programme rather than a single appointment. ![](https://storage.ghost.io/c/93/20/932004ad-b501-4cef-8a02-28e1473c42cb/content/images/2026/10/renal-denervation-blood-pressure-evidence-2-cinematic.jpg) ###